Process for preparing malathion for pharmaceutical use

    公开(公告)号:US08039657B2

    公开(公告)日:2011-10-18

    申请号:US12353678

    申请日:2009-01-14

    IPC分类号: C07F9/02

    摘要: The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes.

    Process for preparing malathion for pharmaceutical use
    32.
    发明授权
    Process for preparing malathion for pharmaceutical use 有权
    制备马拉硫糖用于制药的方法

    公开(公告)号:US07977324B2

    公开(公告)日:2011-07-12

    申请号:US12353691

    申请日:2009-01-14

    IPC分类号: A61K31/66

    摘要: The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes.

    摘要翻译: 本发明提供了制备具有降低的有毒杂质水平的高纯度形式的马拉硫磷的方法。 此外,通过本发明的方法制备的马拉硫磷是储存稳定的。 马拉硫磷中的有毒杂质,例如异马硫磷,O,O,S-三甲基二硫代磷酸酯(MeOOSPS),O,O,S-三甲基硫代磷酸酯(MeOOSPO),O,S,S-三甲基二硫代磷酸酯(MeOSSPO),malaoxon 异马硫磷,富马酸二乙酯,甲基马拉硫磷,二甲基马拉硫磷,O,O-甲基,乙基-S-(1,2-二甲氧基乙氧基)乙基 - 二硫代磷酸酯的含量低于可用于制药目的的任何其他马拉硫磷市售制剂 。

    Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide
    33.
    发明授权
    Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide 有权
    制备5,5-二苯并(b,f)吖庚因-5-甲酰胺的方法

    公开(公告)号:US07723514B2

    公开(公告)日:2010-05-25

    申请号:US11427503

    申请日:2006-06-29

    IPC分类号: C07D223/18

    CPC分类号: C07D223/26 C07D223/28

    摘要: The present invention provides a method of preparing a 5H-dibenz[b,f]azepine-5-carboxamide of formula (1) wherein R1, R2, R3, and R4 are independently selected from the group consisting of hydrogen, halogen, nitro, cyano, carboxyl, A, —CO(A), —OCO(A), —O(A), —N(A)2, —CON(A)2, and —COO(A), wherein A is selected from the group consisting of C1-C10 alkyl, C3-C10 cycloalkyl, C2-C10 alkenyl, C5-C10 cycloalkenyl, C2-C10 alkynyl, and C6-C20 aryl, wherein the two A groups of —N(A)2 and —CON(A)2 can be the same or different, and wherein R2 and R3 can together form a bond; comprising reacting a 5H-dibenz[b,f]azepine of formula (2) with a) a cyanate salt selected from the group consisting of alkali metal cyanate salts and alkaline-earth metal cyanate salts, and b) a salt of an amino compound having no N—H bonds, wherein the salt has a Ka (25° C.) of at least about 10×10−11.

    摘要翻译: 本发明提供制备式(1)的5H-二苯并[b,f]吖庚因-5-甲酰胺的方法,其中R 1,R 2,R 3和R 4独立地选自氢,卤素,硝基, 氰基,羧基,A,-CO(A),-OCO(A),-O(A),-N(A)2,-CON(A)2和-COO(A) 由C 1 -C 10烷基,C 3 -C 10环烷基,C 2 -C 10烯基,C 5 -C 10环烯基,C 2 -C 10炔基和C 6 -C 20芳基构成的基团,其中-N(A)2和-CON (A)2可以相同或不同,并且其中R2和R3可以一起形成键; 包括使式(2)的5H-二苯并[b,f]吖庚因与a)选自碱金属氰酸盐和碱土金属氰酸盐的氰酸盐反应,和b)氨基化合物的盐 不具有N-H键,其中所述盐具有至少约10×10-11的Ka(25℃)。

    Process for preparing 1-methoxymethyl 5,5-diphenybarbituric acid
    34.
    发明申请
    Process for preparing 1-methoxymethyl 5,5-diphenybarbituric acid 审中-公开
    1-甲氧基甲基-5,5-二苯基巴比妥酸的制备方法

    公开(公告)号:US20070167624A1

    公开(公告)日:2007-07-19

    申请号:US11727557

    申请日:2007-03-27

    IPC分类号: C07D239/62

    CPC分类号: C07D239/62

    摘要: The present invention provides a novel process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid. In particular, the present invention provides a process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid by reacting 1,3-bis(methoxymethyl)-5,5-diphenylbarbituric acid with a Lewis acid to selectively remove one methoxymethyl group from 1,3-bis(methoxymethyl)-5,5-diphenylbarbituric acid.

    摘要翻译: 本发明提供一种制备1-甲氧基甲基-5,5-二苯基巴比妥酸的新方法。 特别地,本发明提供了通过使1,3-双(甲氧基甲基)-5,5-二苯基巴比妥酸与路易斯酸反应来制备1-甲氧基甲基-5,5-二苯基巴比妥酸的方法,以选择性地从1 ,3-双(甲氧基甲基)-5,5-二苯基巴比妥酸。

    Process for preparing a crystalline form of halobetasol propionate
    35.
    发明申请
    Process for preparing a crystalline form of halobetasol propionate 审中-公开
    制备结晶形式的丙酸halobetasol的方法

    公开(公告)号:US20070167420A1

    公开(公告)日:2007-07-19

    申请号:US11399732

    申请日:2006-04-06

    CPC分类号: C07J7/0085 C07J7/00

    摘要: The present invention provides a process for preparing a crystalline form of halobetasol propionate, comprising the step of crystallizing halobetasol propionate from absolute ethanol or a mixture of ethanol and water, wherein the crystalline form of halobetasol propionate is characterized by an x-ray powder diffraction pattern having peaks at 10.0, 11.6, 12.9, 13.4, 14.5, 16.4, 17.6, and 23.5±0.2 degrees 2θ.

    摘要翻译: 本发明提供了一种制备结晶形式的丙酸卤代倍他索的方法,其包括从无水乙醇或乙醇和水的混合物中结晶丙酸偏氧胆硫醇的步骤,其中丙酸卤代倍他索的结晶形式的特征在于X-射线粉末衍射图 在10.0,11.6,12.9,13.4,14.5,16.4,17.6和23.5±0.2度2θ处具有峰。

    Process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
    36.
    发明授权
    Process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid 失效
    1-甲氧基甲基-5,5-二苯基巴比妥酸的制备方法

    公开(公告)号:US07227021B2

    公开(公告)日:2007-06-05

    申请号:US11380066

    申请日:2006-04-25

    IPC分类号: C07D239/62 C07D239/66

    CPC分类号: C07D239/62

    摘要: The present invention provides a novel process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid. In particular, the present invention provides a process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid by reacting 1,3-bis(methoxymethyl)-5,5-diphenylbarbituric acid with a Lewis acid to selectively remove one methoxymethyl group from 1,3-bis(methoxymethyl)-5,5-diphenylbarbituric acid.

    摘要翻译: 本发明提供一种制备1-甲氧基甲基-5,5-二苯基巴比妥酸的新方法。 特别地,本发明提供了通过使1,3-双(甲氧基甲基)-5,5-二苯基巴比妥酸与路易斯酸反应来制备1-甲氧基甲基-5,5-二苯基巴比妥酸的方法,以选择性地从1 ,3-双(甲氧基甲基)-5,5-二苯基巴比妥酸。

    Method for the preparation of 6-alpha fluoro corticosteroids
    37.
    发明申请
    Method for the preparation of 6-alpha fluoro corticosteroids 有权
    6-α氟皮质激素的制备方法

    公开(公告)号:US20060247434A1

    公开(公告)日:2006-11-02

    申请号:US11457280

    申请日:2006-07-13

    IPC分类号: C07J71/00

    CPC分类号: C07J71/00 C07J3/00

    摘要: A method for producing a 6α-fluorinated corticosteroid or derivative thereof by reacting a 17-hydroxy-21-ester epoxide of Formula II with a stereoselective fluorinating agent to stereoselectively form a 21-ester-17-hydroxy 6α-fluorinated compound of Formula VII R1 can be OC(O)—Rd; R4 can be C(O)—Rd; R3 can be H or Rd. Each Rd may be the same or different and is independently selected from (C1-4)alkyl, aryl and heteroaryl. The dashed line can be a single or a double bond. R4 may be, for example, acetyl; R3 may be, for example, alpha or beta methyl; R1 may be, for example, acetate or propionate, The stereoselective fluorinating agent used in the reaction may be, for example, a fluoropyridinium or fluoroquinuclidium compound, for example, Selectfluor®.

    摘要翻译: 通过使式II的17-羟基-12-酯环氧化物与立体选择性氟化剂反应来立体选择性地形成式VII R的21-酯-17-羟基6α-氟化化合物来制备6α-氟化皮质类固醇或其衍生物的方法 -R 1可以是OC(O)-R d。 R 4可以是C(O)-R d; R 3可以是H或R d。 每个R d可以相同或不同,并且独立地选自(C 1-4烷基)烷基,芳基和杂芳基。 虚线可以是单键或双键。 R 4可以是例如乙酰基; R 3可以是例如α或β甲基; R 1可以是例如乙酸酯或丙酸酯。反应中使用的立体选择性氟化剂可以是例如氟代吡啶鎓或氟喹喔啉化合物,例如Selectfluor。

    Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide
    38.
    发明授权
    Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide 有权
    制备5,5-二苯并(b,f)吖庚因-5-甲酰胺的方法

    公开(公告)号:US07091339B2

    公开(公告)日:2006-08-15

    申请号:US10460946

    申请日:2003-06-13

    IPC分类号: C07D223/18

    CPC分类号: C07D223/26 C07D223/28

    摘要: The present invention provides a method of preparing a 5H-dibenz[b,f]azepine-5-carboxamide of formula (1) wherein R1, R2, R3, and R4 are independently selected from the group consisting of hydrogen, halogen, nitro, cyano, carboxyl, A, —CO(A), —OCO(A), —O(A), —N(A)2, —CON(A)2, and —COO(A), wherein A is selected from the group consisting of C1–C10 alkyl, C3–C10 cycloalkyl, C2–C10 alkenyl, C5–C10 cycloalkenyl, C2–C10 alkynyl, and C6–C20 aryl, wherein the two A groups of —N(A)2 and —CON(A)2 can be the same or different, and wherein R2 and R3 can together form a bond; comprising reacting a 5H-dibenz[b,f]azepine of formula (2) with a) a cyanate salt selected from the group consisting of alkali metal cyanate salts and alkaline-earth metal cyanate salts, and b) a salt of an amino compound having no N—H bonds, wherein the salt has a Ka (25° C.) of at least about 10×10−11.

    摘要翻译: 本发明提供制备式(1)的5H-二苯并[b,f]吖庚因-5-甲酰胺的方法,其中R 1,R 2,R 2, SO 3,和SO 4独立地选自氢,卤素,硝基,氰基,羧基,A,-CO(A),-OCO(A), -O(A),-N(A)2,-CON(A)2和-COO(A),其中A选自 C 1 -C 10烷基,C 3 -C 10环烷基,C 2 H 2 C 1 -C 10亚烯基,C 5 -C 10环烯基,C 2 -C 10亚烷基, 其中两个A组的-N(A)2 - 和 - CO((C 1 -C 6) A)2可以相同或不同,并且其中R 2和R 3可以一起形成键; 包括使式(2)的5H-二苯并[b,f]吖庚因与a)选自碱金属氰酸盐和碱土金属氰酸盐的氰酸盐反应,和b)氨基化合物的盐 不具有NH键,其中所述盐具有至少约10×10 -11的K a(25℃)。

    Process of preparing a crystalline azithromycin monohydrate
    39.
    发明申请
    Process of preparing a crystalline azithromycin monohydrate 有权
    制备结晶阿奇霉素一水合物的方法

    公开(公告)号:US20060063725A1

    公开(公告)日:2006-03-23

    申请号:US11211011

    申请日:2005-08-24

    IPC分类号: C07H17/08 A61K31/7052

    CPC分类号: C07H17/08

    摘要: The present invention provides a process of preparing a crystalline azithromycin monohydrate. The process involves dissolving azithromycin in a solution containing ethanol, adding the dissolved azithromycin into water to precipitate the crystals, isolating and drying the precipitate to a water content of about 5% (w/w) to about 7% (w/w). The resulting azithromycin monohydrate is stable, exhibiting less than 2% degradation, and non-hydroscopic.

    摘要翻译: 本发明提供一种制备结晶阿奇霉素一水合物的方法。 该方法包括将阿奇霉素溶解在含有乙醇的溶液中,将溶解的阿奇霉素加入水中以沉淀晶体,分离并干燥沉淀物至约5%(w / w)至约7%(w / w)的水含量。 所得阿齐霉素一水合物是稳定的,表现出低于2%的降解和非吸湿性。

    Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom
    40.
    发明申请
    Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom 失效
    由1,2,3,9-四氢-9-甲基-3-亚甲基-4H-咔唑-4-酮和昂丹司琼制备的方法

    公开(公告)号:US20060041004A1

    公开(公告)日:2006-02-23

    申请号:US11204539

    申请日:2005-08-16

    IPC分类号: A61K31/403 C07D209/82

    CPC分类号: C07D403/06 C07D209/88

    摘要: The present invention provides a rapid, high-yielding process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one from 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one without using a secondary amine as a catalyst, and without using glacial acetic acid as a solvent. The present invention further provides a rapid, high-yielding process for preparing ondansetron from 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one without using alumina as a catalyst.

    摘要翻译: 本发明提供了快速,高产出的方法,用于由1,2,3,9-四氢-9(1H) - 酮制备1,2,3,9-四氢-9-甲基-3-亚甲基-4H-咔唑-4-酮 - 甲基-4H-咔唑-4-酮,不使用仲胺作为催化剂,不使用冰醋酸作为溶剂。 本发明还提供了一种用于从1,2,3,9-四氢-9-甲基-3-亚甲基-4H-咔唑-4-酮制备昂丹司琼的快速,高产率的方法,而不使用氧化铝作为催化剂。